Pharmacogenomics · 2012 · 96 citations · 50 references
MedicineClinical PharmacokineticsPharmacologyClinical PharmacologyPharmacogeneticsPharmacogenomicsClinical Implementation Of PharmacogeneticsClinical Implementation Of PharmacogenomicsPharmacogenetic TestingPharmacogenomic Data InterpretationPopulation PharmacogeneticsPopulation PharmacogenomicsBiobanks In PharmacogenomicsCyp2c9 GenotypingDose Error IdentificationGenotype-based Drug DosingPharmacogenomic Association StudiesPharmacogenomic DosingPharmacogenomic ImplicationsWarfarin Pharmacogenetic Testing
AIM: Warfarin pharmacogenomic algorithms reduce dosing error, but perform poorly in non-European-Americans. Electronic health record (EHR) systems linked to biobanks may allow for pharmacogenomic analysis, but they have not yet been used for this purpose. PATIENTS & METHODS: We used BioVU, the Vanderbilt EHR-linked DNA repository, to identify European-Americans (n = 1022) and African-Americans (n = 145) on stable warfarin therapy and evaluated the effect of 15 pharmacogenetic variants on stable warfarin dose. RESULTS: Associations between variants in VKORC1, CYP2C9 and CYP4F2 with weekly dose were observed in European-Americans as well as additional variants in CYP2C9 and CALU in African-Americans. Compared with traditional 5 mg/day dosing, implementing the US FDA recommendations or the International Warfarin Pharmacogenomics Consortium (IWPC) algorithm reduced error in weekly dose in European-Americans (13.5-12.4 and 9.5 mg/week, respectively) but less so in African-Americans (15.2-15.0 and 13.8 mg/week, respectively). By further incorporating associated variants specific for European-Americans and African-Americans in an expanded algorithm, dose-prediction error reduced to 9.1 mg/week (95% CI: 8.4-9.6) in European-Americans and 12.4 mg/week (95% CI: 10.0-13.2) in African-Americans. The expanded algorithm explained 41 and 53% of dose variation in African-Americans and European-Americans, respectively, compared with 29 and 50%, respectively, for the IWPC algorithm. Implementing these predictions via dispensable pill regimens similarly reduced dosing error. CONCLUSION: These results validate EHR-linked DNA biorepositories as real-world resources for pharmacogenomic validation and discovery.
50
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf et al. · New England Journal of Medicine · 2009 · 11.2K citations · Full text
Pharmacology and Management of the Vitamin K Antagonists
Jack Ansell, Jack Hirsh, Elaine M. Hylek et al. · CHEST Journal · 2008 · 2.1K citations
The Pharmacology and Management of the Vitamin K Antagonists
Jack Ansell, Jack Hirsh, L. Poller et al. · CHEST Journal · 2004 · 1.5K citations